Consistent with other reports regarding genotype–phenotype correlations (Table 4), TP53 mutation carriers had a significantly higher portion of HER2+ breast cancer than those without mutations.29 Forty-five percent of TP53 mutation-positive women met LFS criteria. This evidence concerns the gene TP53 and breast carcinoma.